Profusa Outlines Potential Path to $250 Million Revenue by 2030, Driven by Sequential Lumee™ Oxygen and Glucose Monitoring Launches

Rhea-AI Summary

Profusa (Nasdaq: PFSA) outlined a commercialization and revenue roadmap anchored by its Lumee tissue-integrated biosensor platform. The company expects EU commercialization in 2Q 2026 with CE GMED certification anticipated in late 1Q 2026 and projects €600–€800 per procedure and equipment revenue of €30,000–€40,000 per center per year. Profusa stated ~35% European population coverage via intended distributors and forecasted potential revenue of $0.5–$2M in 2026, $9–$13M in 2027, and $200–$250M by 2030.

The company plans US Lumee oxygen launch in 1Q 2027 and EU Lumee glucose in mid-2027, and cited addressable markets and additional analytes that could contribute to 2030 targets.

Positive

• EU commercialization planned for 2Q 2026
• Projected revenue target of $200–$250M by 2030
• Projected $9–$13M potential revenue in 2027
• 35% European population coverage via intended distributors

Negative

• Initial 2026 potential revenue small at $0.5–$2M
• CE GMED certification pending; expected late 1Q 2026
• 2030 targets depend on multiple future indications and launches

Insights

Commercial Strategy Analyst

Profusa presents staged EU then US commercial rollouts with revenue targets to $200–$250 million by 2030.

Profusa plans to commercialize the Lumee tissue-oxygen monitor in the EU beginning 2Q 2026 and to expand into the US and additional indications thereafter. The company discloses concrete unit economics and early revenue scenarios: projected EU procedure pricing of €600–€800 per procedure, equipment revenue of €30,000–€40,000 per center per year, and near-term revenue guidance of $0.5–$2 million in 2026 and $9–$13 million in 2027. These figures outline how procedure volume, center adoption, and new indications drive the top-line path to the stated $200–$250 million target by 2030.

Execution depends on discrete, monitorable milestones and commercial capabilities. Key dependencies include achieving GMED CE certification (anticipated late 1Q 2026), converting intended distributor partnerships into active coverage (company cites ~35% European population coverage via intended channels), scaling manufacturing, and securing payer or hospital adoption at the disclosed price points. Material risks are explicit: timing of regulatory clearance, real-world adoption rates, and successful expansion to additional biomarkers (glucose, lactate, CO2, sodium, ethanol) which the company links to the larger revenue opportunity but has not yet quantified beyond the aggregate target.

Watch the following near-term items: receipt of CE GMED certification and actual first commercial sales after 2Q 2026, reported manufacturing output versus planned throughput, and the company’s ability to book distributor agreements that convert intended coverage into active orders. Expect measurable revenue and adoption updates in 2026 and 2027, with the addition of EU glucose launch in mid-2027 and US oxygen launch in 1Q 2027 as specific inflection points tied to the projection timeline.

EU commercialization expected in early 2026; U.S. entry and expanded indications to follow as digital-health pioneer advances tissue-integrated biosensor platform

BERKELEY, Calif, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, outlines its path to revenue generation led by Lumee tissue oxygen monitoring, with commercialization in the European Union (EU) expected in the beginning of 2Q 2026. 

Following recently-announced manufacturing capabilities, intended distributor partnerships, and commercial and clinical collaboration wins, Profusa estimates it now has approximately 35% of the European population covered through its intended distribution channels.  Combined with expanding coverage in Europe and planned geographic reach into the United States markets, as well as potential additional indications on its Lumee technology platform – such as continuous glucose monitoring – Profusa anticipates $200 to $250 million in potential revenue by 2030.

“We believe Profusa is bringing to market a first-of-its-kind, disruptive biochemistry monitoring platform designed for use both in the clinic and at home,” said Ben Hwang, Ph.D., Profusa’s Chairman and CEO. “Backed by more than a decade of development and over $100 million in investment, our Lumee™ technology enables continuous, real-time measurement of tissue oxygen directly within the body—offering a less invasive, more convenient experience for patients while reducing costs for healthcare systems and insurers through earlier detection and improved disease management.

“Following years of innovation and clinical validation, we are preparing for the commercial launch of Lumee tissue oxygen monitoring in Europe in 2Q 2026, supported by strong momentum from clinicians, patients, and research institutions eager to harness our technology to address conditions with a significant unmet medical need,” Dr. Hwang continued.

“As we begin our commercial journey, Profusa is targeting $200 to $250 million in revenue by 2030, supported by multiple high-growth indications. In tissue oxygen monitoring alone, we estimate a $10.5 billion global addressable market across peripheral artery disease, chronic wounds, and critical limb ischemia—representing more than 716,000 CLI procedures annually in Europe. In addition, current solutions for continuous glucose monitoring serve roughly 9 million type 1 diabetes patients, whereas Lumee’s glucose platform is designed to reach a much broader population of over 500 million people living with type 1, type 2, or pre-diabetes worldwide,” concluded Dr. Hwang.

Fred Knechtel, Profusa’s CFO, said, “We expect to layer on additional indications on our Lumee platform technology over time. Tissue oxygen monitoring revenue in Europe is expected to commence in the second quarter of 2026. With our current pipeline of commercial and clinical collaborations and intended distribution network, we are projecting potential revenue of $0.5 to $2 million in in 2026.

“In 2027, we plan to enter the US tissue oxygen monitoring market in the first quarter and add continuous glucose monitoring in the EU in mid-2027. Projected potential revenue in 2027 is $9 to $13 million. In parallel, additional conditions for evaluation – through expected partnerships or licensing agreements – include lactate, carbon dioxide, sodium, and ethanol, which we expect will all contribute to 2030’s projected potential revenue. We look forward to executing on this aggressive and dynamic growth agenda,” Mr. Knechtel concluded.

• 2026 potential revenue is targeted to be $0.5 to $2 million
  • EU Lumee oxygen revenue commences in 2Q 2026
  • Revenue projected to be €600 – €800 per procedure
  • Equipment revenue projected to be €30-000 – €40,000 per center per year (3-4 kits per center)
  • EU CE marking GMED certification anticipated late 1Q 2026
• 2027 potential revenue is targeted to be $9 to $13 million
  • US Lumee Oxygen anticipated launch in 1Q 2027   
  • EU Lumee Glucose anticipated launch in mid-2027
• 2030 potential revenue is targeted to be $200 to $250 million
  • US/EU Lumee Oxygen targeted revenue to be $100 to $120 million
  • US/EU Lumee additional indications including glucose targeted revenue to be $100 to $130 million

About Profusa
Based in Berkeley, Calif., Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.

“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.

For more information, visit https://profusa.com.

Special Note Regarding Forward-Looking Statements
Certain statements in this press release (this “Press Release”) may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in the definitive proxy/final prospectus relating to the business combination, which has been filed with the SEC, and in other documents filed by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.

Contacts
Investor and Media Contacts
email:  info@coreir.com
phone:  1 (212) 655-0924

FAQ

When will Profusa (PFSA) begin commercial sales of Lumee oxygen in Europe?

Profusa targets 2Q 2026 for EU Lumee tissue oxygen commercialization.

What revenue does Profusa (PFSA) project for 2026, 2027, and 2030?

Profusa projects $0.5–$2M in 2026, $9–$13M in 2027, and $200–$250M by 2030.

What regulatory milestone does Profusa cite before EU launch of Lumee tissue oxygen?

Profusa expects CE marking GMED certification anticipated in late 1Q 2026.

When does Profusa plan to enter the US market with Lumee oxygen (PFSA)?

Profusa plans a US Lumee oxygen launch in 1Q 2027.

What commercial launches are planned for Lumee glucose and when?

Profusa expects EU Lumee glucose launch in mid-2027.

What per-procedure and equipment revenue assumptions underlie Profusa's forecasts?

Assumptions include €600–€800 per procedure and €30,000–€40,000 per center/year.